Data presentation at British Thoracic Society Winter Meeting

REYKJAVIK, ICELAND – 17 November 2025 – EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics for chronic respiratory diseases, will be presenting data on its lead asset, glasmacinal (EP395) at the British Thoracic Society (BTS) Winter Meeting, on 26-28 November in London, UK.

The presentation, ‘EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients’, will highlight preclinical data produced through EpiEndo’s collaboration with Lund University. The Lund team investigated the effect of glasmacinal on rhinovirus-induced antiviral and pro-inflammatory responses in bronchial epithelial cells from asthma patients.

Dr Ginny Norris, EpiEndo’s CMO commented:

“This data builds on the knowledge gained from our clinical study in which glasmacinal enhanced the host defence response to inhaled lipopolysaccharide*. Together these data support the potential for glasmacinal to be an effective treatment for reducing exacerbations of respiratory disease irrespective of the trigger.’’

The abstract for the presentation and data can be found here. The presentation will be given by Professor Lena Uller of Lund University, full details below.

Spoken Session: S56-S61 Impact of infection on disease mechanisms

Title: EP395, a novel non-antibiotic macrolide, enhances antiviral responses in bronchial epithelial cells from asthma patients

Time and Date: 9.05am, 27 November 2025

Location: QEII Centre, London, room St James, 4^th Floor

*Hohlfeld J, Badorrek P, Breuer O, et al (2025) Effect of EP395, a novel anti-inflammatory macrolide, an inhaled lipopolysaccharide challenge model in healthy volunteers: a randomised controlled trial. Pulm Pharmacol Ther 90:102365

-ENDS-

Contact:

EpiEndo Pharmaceuticals:
Maria Bech, CEO
+354 454 0090­­­

Vigo Consulting (media relations):
Rozi Morris
+44 20 7390 0230
epiendo@vigoconsulting.com

About EpiEndo Pharmaceuticals (www.epiendo.com)

EpiEndo is a clinical-stage biopharmaceutical company with a unique approach to chronic respiratory diseases that focuses on the role of epithelial function in various inflammatory disorders.

EpiEndo’s new class of orally available macrolides, with reduced antimicrobial resistance (AMR) potential, known as ‘Barriolides™’, show promise as first-in-class therapeutics for chronic respiratory diseases as well as other inflammatory indications. EpiEndo’s lead asset, EP395, was the first Barriolide™ to enter clinical trials, for chronic obstructive pulmonary disease (COPD).

EP395 aims to be the first on-market oral, barrier-enhancing and anti-inflammatory drug, which has the potential to be a unique and impactful treatment option for COPD patients. According to the WHO, COPD is the third leading cause of death globally, and the global economic burden of COPD is projected to cost $4.8 trillion by 2030.